Argos Therapeutics' Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes

Argos Therapeutics announces Phase 2 data showing strong response for the treatment of renal cell carcinoma.... [more]

View complete Press Release article